P2RY12 and COVID-19: The median number of organ support-free days was 21 days (interquartile range [IQR], 20–21 days) among patients in the P2Y12 ADPRB group and 21 days (IQR, 21–21 days) in the standard treatment group (adjusted OR, 0.83 [95% credible interval (CrI), 0.55–1.25]), and a major bleeding event occurred in six patients (2.0%) in the P2Y12 ADPRB group and in two patients (0.7%) in the control group; so no benefit of P2Y12 ADPRB was found in a group of non-critically ill COVID-19 patients with a higher risk of bleeding [42].